Comparative Pharmacology
Head-to-head clinical analysis: DACARBAZINE versus ZEPZELCA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DACARBAZINE versus ZEPZELCA.
DACARBAZINE vs ZEPZELCA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alkylating agent; inhibits DNA and RNA synthesis by forming covalent bonds with DNA, leading to cross-linking and strand breaks. Also inhibits purine synthesis and has some activity as a methylating agent.
Lurbinectedin is a selective inhibitor of oncogenic transcription. It binds to the minor groove of DNA, inhibiting the activity of RNA polymerase II and promoting its degradation, thereby reducing transcription of certain oncogenes and inducing apoptosis in cancer cells.
2.4-4.5 mg/kg IV daily for 10 days every 28 days; or 250 mg/m2 IV daily for 5 days every 21 days; or 375-450 mg/m2 IV single dose every 21-28 days.
3.24 mg/m2 intravenously over 60 minutes every 21 days until disease progression or unacceptable toxicity.
None Documented
None Documented
Clinical Note
moderateDacarbazine + Digoxin
"Dacarbazine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDacarbazine + Digitoxin
"Dacarbazine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDacarbazine + Deslanoside
"Dacarbazine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDacarbazine + Acetyldigitoxin
"Dacarbazine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life: 5 hours (range 3-8 h) after IV administration; biphasic decay with initial half-life ~19 min.
Terminal elimination half-life is approximately 7-9 hours in patients with normal hepatic function, supporting once-daily dosing.
Renal: 40-50% unchanged; hepatic: 30-50% as metabolites (primarily 5-aminoimidazole-4-carboxamide); <10% fecal.
Primarily hepatic metabolism, with biliary/fecal excretion as the major route (approximately 60-80% of the administered dose). Renal excretion accounts for <20% of the dose as unchanged drug and metabolites.
Category D/X
Category C
Alkylating Agent
Alkylating Agent